Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of Youkenafil Hydrochloride, a Phosphodiesterase Type 5 Inhibitor, in Healthy Chinese Male Volunteers
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1108
Abstract: Youkenafil hydrochloride is a novel selective phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. Its safety, tolerability, and pharmacokinetics were evaluated in healthy Chinese male volunteers. In addition, this study explored the effect… read more here.
Keywords: tolerability; type inhibitor; phosphodiesterase type; tolerability pharmacokinetics ... See more keywords
Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV‐INHIBITION study design
Sign Up to like & getrecommendations! Published in 2020 at "ESC Heart Failure"
DOI: 10.1002/ehf2.12630
Abstract: In univentricular hearts, selective lung vasodilators such as phosphodiesterase type 5 (PDE5) inhibitors would decrease pulmonary resistance and improve exercise tolerance. However, the level of evidence for the use of PDE5 inhibitors in patients with… read more here.
Keywords: phosphodiesterase type; inhibition study; heart; design ... See more keywords
Evaluation of combined therapeutic effects of hydrogen sulfide donor sodium hydrogen sulfide and phosphodiesterase type‐5 inhibitor tadalafil on erectile dysfunction in a partially bladder outlet obstructed rat model
Sign Up to like & getrecommendations! Published in 2020 at "Neurourology and Urodynamics"
DOI: 10.1002/nau.24333
Abstract: To evaluate the impacts of hydrogen sulfide (H2S) donor, sodium hydrogen sulfide (NaHS), and phosphodiesterase type‐5 inhibitor (PDE5i), tadalafil per se and their combination treatment on partial bladder outlet obstruction (PBOO)‐induced erectile dysfunction (ED). read more here.
Keywords: phosphodiesterase type; hydrogen; sodium hydrogen; type inhibitor ... See more keywords
Revisiting the halogen bonding between phosphodiesterase type 5 and its inhibitors
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Molecular Modeling"
DOI: 10.1007/s00894-018-3897-z
Abstract: Halogenated ligands are nowadays commonly designed in order to increase their potency against protein targets. Although novel computational methods of evaluating the affinity of such halogenated inhibitors have emerged, they still lack the sufficient accuracy,… read more here.
Keywords: phosphodiesterase type; halogen bonding; bonding phosphodiesterase; type inhibitors ... See more keywords
Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast
Sign Up to like & getrecommendations! Published in 2017 at "International Urology and Nephrology"
DOI: 10.1007/s11255-017-1671-2
Abstract: PurposeTo prove that phosphodiesterase type-4 inhibitors could potentially treat obesity-associated overactive bladder through modulation of the systemic inflammatory response.MethodsIn this 12-week study, 90 female Sprague–Dawley rats were divided into three groups: (1) vehicle-treated normal diet… read more here.
Keywords: phosphodiesterase type; treatment; bladder; associated overactive ... See more keywords
The phosphodiesterase type 4 inhibitor roflumilast suppresses inflammation to improve diabetic bladder dysfunction rats
Sign Up to like & getrecommendations! Published in 2018 at "International Urology and Nephrology"
DOI: 10.1007/s11255-018-2038-z
Abstract: PurposeTo demonstrate that phosphodiesterase type 4 (PDE4) inhibitors could potentially treat diabetic bladder dysfunction (DBD) through modulation of the systemic inflammatory response.MethodsIn this 6-week study, 60 female Sprague–Dawley rats were divided into three groups: (i)… read more here.
Keywords: bladder dysfunction; phosphodiesterase type; bladder; diabetic bladder ... See more keywords
The use of antimuscarinics, phosphodiesterase type V inhibitors and phytotherapy for lower urinary tract symptoms in men
Sign Up to like & getrecommendations! Published in 2017 at "Asian Journal of Urology"
DOI: 10.1016/j.ajur.2017.05.002
Abstract: Besides the mainstay of α-blockers and 5α-reductase inhibitors, other forms of medical therapy complete the armamentarium in the treatment of lower urinary tract symptoms (LUTS) in men. These treatments can target specific symptoms as well… read more here.
Keywords: urinary tract; phosphodiesterase type; tract symptoms; type inhibitors ... See more keywords
EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil
Sign Up to like & getrecommendations! Published in 2018 at "Sexual Medicine"
DOI: 10.1016/j.esxm.2017.10.003
Abstract: Introduction Erectile dysfunction (ED) is a multidimensional disorder with an estimated prevalence of 1% to 10% in men younger than 40 years and up to 100% in men in their 70s and 80s. Aim To… read more here.
Keywords: phosphodiesterase type; generation; type inhibitors; real life ... See more keywords
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.9b00123
Abstract: Phosphodiesterase type 5 (PDE5) inhibitors are first-line therapy for pulmonary arterial hypertension (PAH) and erectile dysfunction. As a continuing work to improve the terminal half-lives and oral bioavailabilities of our previously reported 4(3 H)-pyrimidones, a… read more here.
Keywords: phosphodiesterase type; driven optimization; pharmacokinetics driven; arterial hypertension ... See more keywords
Impact of postoperative phosphodiesterase type 5 inhibitor treatment on lower urinary tract symptoms after robot-assisted radical prostatectomy: a longitudinal study
Sign Up to like & getrecommendations! Published in 2017 at "Scandinavian Journal of Urology"
DOI: 10.1080/21681805.2016.1250810
Abstract: Abstract Objective: This study aimed to assess the role of tadalafil, a phosphodiesterase type 5 inhibitor (PDE5-I), in recovery of lower urinary tract symptoms (LUTS) after robot-assisted radical prostatectomy (RARP). Materials and methods: All patients… read more here.
Keywords: phosphodiesterase type; patients taking; treatment; study ... See more keywords
Risk of nonarteritic ischaemic optic neuropathy with phosphodiesterase type 5 inhibitors: a systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2019 at "Acta Ophthalmologica"
DOI: 10.1111/aos.14253
Abstract: The development of nonarteritic anterior ischaemic optic neuropathy has been described to phosphodiesterase type 5 inhibitors. The aim of this systematic review and meta‐analysis was to assess the risk of nonarteritic anterior ischaemic optic neuropathy… read more here.
Keywords: type inhibitors; optic neuropathy; phosphodiesterase type; ischaemic optic ... See more keywords